{
  "id": 19786134,
  "title": "Intellia stock price target maintained at $30 by Citizens on HAE data",
  "url": "https://urgent.news/2026/11/13/intellia-stock-price-target-maintained-at-30-by-citizens-on-hae-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T09:20:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/intellia-stock-price-target-maintained-at-30-by-citizens-on-hae-data-93CH-5024584"
  },
  "original_language": "en",
  "account": "Citizens maintained a $30 price target on Intellia Therapeutics (NASDAQ:NTLA) shares, following data updates on its lonvo-z treatment for hereditary angioedema. The firm reported that 100% of patients were free from long-term prophylaxis and two-thirds attack-free during the ACAAI presentation. Intellia showcased additional duration data and garnered significant patient demand for the therapy, supported by key opinion leaders. The company's sum-of-the-parts analysis values the HAE opportunity at $20 per share, while Intellia's shares currently trade at $10.55 with a market cap of $1.48 billion. InvestingPro analysis suggests the biotech is undervalued, with more cash than debt on its balance sheet and a robust current ratio of 6.31. However, the company is rapidly depleting cash, which is common for development-stage therapeutics firms. The one-and-done lonvo-z treatment offers attack reductions without continuous therapy. Recent financing around lonvo-z strengthens the HAE opportunity. Intellia Therapeutics is scheduled to report earnings on November 6, leading to options data hinting at a potential 3.8% stock movement. The FDA has accepted lonvo-z's Biologics License Application, granted priority review, and set a Prescription Drug User Fee Act target action date of March 10, 2027. This could make lonvo-z the first in vivo CRISPR-based therapy for hereditary angioedema, positioning Intellia Therapeutics favorably in the biotech landscape.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}